Chimerix Inc. Daily Stock Analysis

Daily Stock Analysis, CMRX, Chimerix Inc, priceseries

Chimerix Inc. Daily Stock Analysis
Stock Information
Open
5.58
Close
5.38
High
5.78
Low
5.32
Previous Close
5.55
Daily Price Gain
-0.17
YTD High
7.02
YTD High Date
Jan 4, 2022
YTD Low
4.93
YTD Low Date
Feb 24, 2022
YTD Price Change
-1.42
YTD Gain
-20.88%
52 Week High
10.47
52 Week High Date
Mar 15, 2021
52 Week Low
4.75
52 Week Low Date
Nov 4, 2021
52 Week Price Change
-3.61
52 Week Gain
-40.16%
Recent priceSeries Trade Signals

These are sample algorithmic trades based on actual market data.

Trade Type
Entry Date
Entry Price
Exit Date
Exit Price
Trade Hold Time
Gain
Trade Record
LONG
Feb 27. 2017
5.67
Mar 16. 2017
6.22
13 Trading Days
9.64%
Link
LONG
Dec 21. 2017
4.44
Jan 11. 2018
4.71
13 Trading Days
6.16%
Link
LONG
Mar 5. 2018
5.18
Mar 19. 2018
5.51
10 Trading Days
6.40%
Link
LONG
May 10. 2019
3.12
May 30. 2019
3.51
13 Trading Days
12.38%
Link
LONG
Jun 26. 2019
3.49
Jul 8. 2019
3.90
7 Trading Days
11.77%
Link
LONG
Sep 10. 2019
2.11
Sep 30. 2019
2.35
14 Trading Days
11.36%
Link
LONG
Oct 31. 2019
1.43
Dec 10. 2019
2.23
27 Trading Days
55.97%
Link
LONG
Apr 29. 2020
2.15
May 19. 2020
3.05
14 Trading Days
42.03%
Link
LONG
Jul 15. 2020
3.23
Jul 24. 2020
3.49
7 Trading Days
8.03%
Link
LONG
Nov 3. 2020
2.82
Nov 19. 2020
3.28
12 Trading Days
16.29%
Link
LONG
Nov 20. 2020
3.33
Dec 1. 2020
3.50
6 Trading Days
5.01%
Link
LONG
Dec 4. 2020
3.62
Dec 22. 2020
5.02
12 Trading Days
38.80%
Link
LONG
Jan 7. 2021
4.98
Jan 29. 2021
8.62
15 Trading Days
73.07%
Link
LONG
Dec 21. 2021
6.15
Dec 31. 2021
6.54
7 Trading Days
6.35%
Link
LONG
Feb 25. 2022
5.63
Mar 1. 2022
5.94
2 Trading Days
5.51%
Link
Company Information
Stock Symbol
CMRX
Exchange
NasdaqGM
Company URL
http://www.chimerix.com
Company Phone
919.806.1074
CEO
M. Michelle Berrey
Headquarters
North Carolina
Business Address
2505 MERIDIAN PARKWAY, SUITE 100, DURHAM, NC 27713
Sector
Equity
Industry Category
Drugs
Industry Group
Biotechnology
CIK
0001117480
About

Chimerix, Inc. engages in the research, development, and commercialization of pharmaceutical products. Its portfolio includes Brincidofovir for the treatment of adenovirus, cytomegalovirus, and smallpox. The company was founded by George R. Painter, III and Timothy Wollaeger in April 2000 and is headquartered in Durham, NC.

Description

Chimerix, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines that address unmet medical needs in the United States. The company's lead product candidate is brincidofovir, an investigational nucleoside analog for the prevention of serious viral infections in hematopoietic or stem cell transplant recipients (HCT), as well as for the treatment of serious adenovirus infection and disease, smallpox, and BK virus infection in kidney and HCT transplant recipients. It is also developing CMX521, a nucleoside analog that is in preclinical stage for the treatment and prevention of norovirus; and CMX157, a nucleoside analog, which is in Phase II clinical stage to treat HIV and hepatitis B virus infection. It has a license agreement with ContraVir Pharmaceuticals for the development and commercialization of brincidofovir and CMX157 for certain antiviral indications; and BARDA for the development of brincidofovir for the treatment of smallpox. Chimerix, Inc. was founded in 2000 and is headquartered in Durham, North Carolina.

TCHANNELS® is a Registered Trademark with USPTO

Some images used on this site have been taken from Unsplash

Legal Information

Useful Links

Contact Us

PO Box 2574, Sunnyvale
California 94087-0574, USA
Phone: 408-940-5056
Email: Click to send us an Email

Risks of Algorithmic Trading: Before investing please read our disclosure on Risks of Algorithmic Trading.

DISCLAIMER All investments entail inherent risk. This research seeks to assist investors in determining when to buy and when to sell to attempt to maximize profits or minimize losses. All final investment decisions are yours and as a result you could make or lose money. priceSeries.com, its employees and/or its affiliates and family members may from time to time take positions in the open market or otherwise with respect to the securities discussed. priceSeries.com, its employees and/or affiliates do not have stock ownership equal to or greater than 1% of the outstanding stock of the covered company nor does any employee of priceSeries.com sit on the Board of Directors of any covered company. priceSeries.com is not a broker/dealer, and the firm does not underwrite securities, manage assets or perform investment banking activities. The statements made herein include information obtained from sources believed to be reliable, but no independent verification has been made and we do not guarantee its accuracy or completeness.

U.S. Government Required Disclaimer - Commodity Futures Trading Commission
Futures and Options trading has large potential rewards, but also large potential risk. You must be aware of the risks and be willing to accept them in order to invest in the futures and options markets. Don't trade with money you can't afford to lose. This is neither a solicitation nor an offer to Buy/Sell futures or options. No representation is being made that any account will or is likely to achieve profits or losses similar to those discussed on this web site. The past performance of any trading system or methodology is not necessarily indicative of future results.

CFTC RULE 4.41 - HYPOTHETICAL OR SIMULATED PERFORMANCE RESULTS HAVE CERTAIN LIMITATIONS. UNLIKE AN ACTUAL PERFORMANCE RECORD, SIMULATED RESULTS DO NOT REPRESENT ACTUAL TRADING. ALSO, SINCE THE TRADES HAVE NOT BEEN EXECUTED, THE RESULTS MAY HAVE UNDER-OR-OVER COMPENSATED FOR THE IMPACT, IF ANY, OF CERTAIN MARKET FACTORS, SUCH AS LACK OF LIQUIDITY. SIMULATED TRADING PROGRAMS IN GENERAL ARE ALSO SUBJECT TO THE FACT THAT THEY ARE DESIGNED WITH THE BENEFIT OF HINDSIGHT. NO REPRESENTATION IS BEING MADE THAT ANY ACCOUNT WILL OR IS LIKELY TO ACHIEVE PROFIT OR LOSSES SIMILAR TO THOSE SHOWN.

2016 © priceSeries.com All Rights Reserved. Privacy Policy | Subscriber Agreement | Risks of Algorithmic Trading